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Abstract
Purpose To summarize current knowledge on upper urinary tract carcinoma (UTUC) regarding risk stratification, long-term 
results, and follow-up.
Methods A scoping review approach was applied to search literature in Pubmed, Web of Science, and Embase. Consensus 
was reached through discussions at Consultation on UTUC, September 2018, Stockholm.
Results To optimize oncological outcome considering both cancer-specific survival (CSS) and overall survival (OS), it is 
essential to identify pre- and postoperative prognostic factors. In low-risk UTUC, kidney-sparing surgery (KSS) and radi-
cal nephroureterectomy (RNU) offer equivalent CSS, whereas RNU may result in poorer OS due to nephron loss. For more 
aggressive tumours, undergrading can lead to insufficient treatment. The strongest prognostic factors are tumour stage and 
grade. Determining grade is best achieved by ureterorenoscopy (URS) with focal samples, biopsy and cytology. Staging 
is more difficult but can be indirectly achieved by multiphase computed tomography urography (CTU) or tumour grade 
determined by cytology and histopathology. Patients treated with KSS should be monitored closely with regular follow-ups 
(URS and CTU).
Conclusion KSS should be offered in low-risk UTUC when feasible, whereas RNU is the treatment of choice in organ-
confined high-risk UTUC. Intravesical recurrence (IVR) is common after RNU, but a single postoperative dose of mitomycin 
instillation decreases IVR. Endourological management has high local and bladder recurrence rates; however, its effect on 
CSS or overall survival OS is unclear. RNU is associated with significant risk of chronic kidney disease. Careful selection 
of patients and risk stratification are mandatory, and patients should be followed according to strict protocols.
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Introduction
Although urothelial carcinoma is the fourth most common 
tumour type, urothelial carcinoma of the upper urinary tract 
(UTUC) is rare and accounts for only 5–10% of urothelial 
cancers [1], with an estimated annual incidence of nearly two 
cases per 100,000 inhabitants in Western countries. Smok-
ing is the most important risk factor for UTUC, increas-
ing the relative risk (RR) 2.5- to 7-fold [2]. Unlike bladder 
urothelial carcinoma where approximately 25% are invasive 
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at diagnosis, 40–60% of UTUCs are invasive at diagnosis [3, 
4]. UTUC is more common at the ages greater than 70 years, 
and is three times more common in men.
The current guidelines outlined by the European Associa-
tion of Urology (EAU) divide UTUC into low- and high-risk 
disease [5]. The goal of risk stratification is to reduce the 
risks of understaging, undergrading, and overtreatment, and 
to select the best treatment option for long-term health.
Radical nephroureterectomy has previously been the gold 
standard for treatment of UTUC. However, with the emer-
gence of endoscopic techniques, a number of studies have 
indicated that kidney-sparing surgery (KSS) and treatment 
with radical nephroureterectomy (RNU) offer equivalent 
long-term CSS in patients with low-risk UTUC [6, 7]. RNU 
is recommended for organ-confined high-risk UTUC [5]. 
Inasmuch as UTUC is a relatively rare disease, most recom-
mendations for clinical decision-making are based on retro-
spective studies. Tumour stage and grade have proven to be 
the strongest prognostic factors [3, 8], and some studies have 
reported that size and multifocality are not as decisive [9].
When considering treatment options, it is essential to cor-
rectly identify high-risk UTUC, because KSS can represent 
undertreatment, and RNU unequivocally results in loss of 
renal function and risk of chronic kidney disease (CKD), 
both of which are known to be associated with increased 
risk of morbidity and mortality [10]. Thus, both prognos-
tic tumour characteristics and general health variables of 
the patient should be taken into consideration (Fig. 1). The 
choice of treatment also depends on whether an approach is 
regarded as elective, relative, imperative, or palliative.
Clearly, risk stratification must be optimized to achieve 
safe and personalized management of UTUC.
This review aims to consider the challenges in risk strati-
fication of UTUC by discussing different prognostic factors, 
follow-up, and long-term results after different treatment 
modalities in UTUC by expanding the current recommenda-
tions, and showing directions for future research. A scoping 
review approach was applied to search literature in Pubmed, 
Web of Science, and Embase.
Risk stratification
To predict prognosis and determine whether KSS might be 
more beneficial than radical extirpative surgery, risk strati-
fication is a very important part of the clinical decision-
making for patients with UTUC [11].
As mentioned above, the EAU guidelines categorize 
UTUC into low- and high-risk diseases [5]. Low-risk UTUC 
is defined as follows (all criteria must be fulfilled): a unifocal 
tumour with a size of < 2 cm, low-grade cytology and histol-
ogy (URS biopsy), and non-invasive aspects on computed 
tomography urography (CTU). High-risk UTUC is defined 
as the presence of one or more of the following criteria: 
hydronephrosis, tumour size > 2 cm, high-grade cytology 
Fig. 1  Personalized manage-
ment of UTUC. Before making 
a treatment decision, all 
variables must be taken into 
consideration, including patient-
related aspects and tumour biol-
ogy. BMI body mass index
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or histopathology (biopsy), multifocal disease, or previous 
radical cystectomy for bladder cancer.
Other preoperative risk factors that should be taken into 
consideration are tobacco consumption, advanced age, 
BMI > 30, and presence of comorbidity.
Nevertheless, both preoperatively and postoperatively, by 
far the strongest prognostic factors are stage and grade, fol-
lowed by presence of carcinoma in situ (CIS), performance 
of bladder cuff excision or not at RNU (where not perform-
ing bladder cuff excision increases the risk), lymphovascu-
lar invasion, lymph node involvement, tumour architecture, 
positive surgical margins, tumour necrosis, molecular mark-
ers, and histological variant [5].
The best tool for preoperative grading is ureterorenos-
copy with simultaneous collection of samples for cytology 
and histopathology [12–14]. Also, various models have been 
proposed for further risk stratification. Favaretto et al. [15] 
published a scoring system for the prediction of muscle-
invasive and non-organ-confined UTUC, which consisted 
of a preoperative multivariable model that combined uret-
eroscopy variables and imaging. This system has not been 
validated by the researchers. Rouprêt and co-workers [16] 
developed a nomogram for the prediction of CSS after RNU 
for UTUC; postoperative variables are plotted in the nomo-
gram, and the 5-year CSS is calculated. A limitation of this 
system is that it uses postoperative prognostic calculations 
that cannot aid preoperative treatment decisions.
As mentioned, UTUC is a rare disease, and hence scien-
tists have often tried to draw comparisons between UTUC 
and bladder cancer. However, in reality, the two diseases 
are like disparate twins, that is, they share many features 
but differ in several aspects, including anatomical, biologi-
cal, and molecular dissimilarities that warrant considera-
tion in clinical decision-making [17]. Another risk factor for 
UTUC is hereditary non-polyposis colon cancer (HNPCC) 
or Lynch syndrome, which should be suspected in patients 
aged < 60  years or with a personal history of HNPCC-
spectrum cancer. Patients with HNPCC have a cumulated 
risk of 1–28% of developing UTUC during their lifetime 
[18]. Nearly 20 years ago, tumour microsatellite instability 
(MSI) was first described as a predictor of survival in 95% 
of all patients with HNPCC syndrome [19]. In 2005, Rouprêt 
et al. [20] studied the impact of MSI in advanced UTUC and 
found that the survival rate was higher in patients who had 
MSI than in those who did not. The role of germline DNA 
mutations has also been discussed. It has been shown that 
genetic polymorphisms on 8q24.1 and 4p16.3 are associ-
ated with aggressive UTUC but not with bladder cancer. 
It has also been reported that genetic variability in 8q24 
leads to greater risk of developing UTUC, and that the T/T 
genotype is associated with aggressiveness of this disease. 
Moreover, a retrospective study of 83 tumours revealed that 
only two alterations were uniformly associated with high 
grade and advanced stage of a tumour [21]: TP53/MDM2 
alterations, which were associated with poor prognosis, and 
FGFR3 mutations, which were associated with more favour-
able outcome.
Long‑term results
Most surgical series have limited follow-up and are retro-
spective, and thus it can be difficult to compare the results. 
The EAU guidelines panel [22] reviewed 42 studies that 
compared open and laparoscopic RNU. A total of 7554 
patients were included in the 42 investigations (median 36 
patients per arm), and the techniques used varied. The risk of 
bias and confounding was high in most of the reviewed stud-
ies. Only one of the 42 investigations was a randomized clin-
ical trial (n = 80) [23], and only four of the studies (including 
a total of 300 patients) had at least 5 years of follow-up 
[24–27]. Furthermore, only nine of the studies adjusted for 
risk factors. Port-site metastasis rates ranged from 0% to 
2.8%. The EAU guidelines panel concluded that open RNU 
may be a better choice for patients with pT3/pT4 disease.
Seisen et al. [28] conducted a multi-centre retrospective 
analysis of 304 patients who had unifocal distal ureteral 
tumours treated with RNU (n = 128), distal ureterectomy 
(n = 134), or endoscopic ablation (n = 42). The mean follow-
up time was 30.7 months. The results showed that OS was 
better for patients treated with KSS (i.e., ureterectomy or 
ablation), although CSS was similar for all three treatment 
groups. In another evaluation, the EAU guidelines panel 
[29] reviewed 22 retrospective studies that compared RNU 
with different methods of KSS [i.e., segmental ureterectomy, 
ureterorenoscopy (URS), or a percutaneous approach] for 
treatment of UTUC. This analysis revealed that survival in 
patients with low-grade and non-invasive UTUC after RNU 
was similar to survival noted after KSS with URS or the 
percutaneous approach. Furthermore, considering high-
grade and invasive UTUC, selected patients benefited from 
selected ureterectomy (when feasible), with similar onco-
logic outcomes as after RNU. Nevertheless, it can be con-
cluded that, in general, the data presented in the reviewed 
studies were poorly reported, and there was a selection bias 
in favour of KSS.
Grasso et al. [6] summarized 15 years of experience 
of 160 UTUC patients treated between January 1996 and 
August 2011. The patients were divided into three distinct 
groups based on endoscopic samples and treatment type: 
group 1, low-grade lesions treated with URS (n = 66); group 
2, high-grade lesions palliatively treated with URS (n = 16); 
group 3, high- or low-grade lesions treated with extirpative 
surgery (RNU; n = 80). The patients with low-grade disease 
treated with URS with curative intent (group 1) had 2-, 5-, 
and 10-year CSS rates of 98%, 87% and 81%, respectively; 
the corresponding figures for patients treated with RNU 
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(group 3) were 97%, 87%, and 78%. The patients with high-
grade disease and treated with RNU had 2-, 5-, and 10-year 
CSS of 70%, 53%, and 38%, and metastasis-free survival of 
55%, 45%, and 35%, respectively. For patients with high-
grade disease treated with palliative URS, median survival 
was 29.2 months, and 2-year OS was 54%. Ten patients who 
initially had low-grade UTUC treated with KSS progressed 
to high-grade disease at a mean time of 38.5 months.
In another paper, Cutress et al. [30] described 20 years of 
experience of endoscopic treatment of UTUC in 73 patients 
with a mean follow-up of 62.8 months. Disease-specific 
survival was 88.9% at 5 years and 77.4% at 10 years for all 
grades. Furthermore, outcome was much better for grade 1 
(G1) tumours than for grade 3 (G3) tumours with regard to 
disease-specific survival, upper tract and bladder recurrence-
free survival, renal unit survival, upper tract progression-free 
survival, and endoscopic failure-free survival. The results for 
grade 2 (G2) tumours were in between those noted for G1 
and G3 lesions.
Keeley et al. [31] published the outcomes in 38 patients 
(41 kidneys) treated with KSS and followed endoscopically 
for a mean of 35 months. Tumour grading was possible in 
40/41 kidneys. Low-grade tumours (G1 or G1–G2) were 
found in 21 renal units (19 patients), G2 in 14, and G3 in 
five. The patients had undergone more than 200 procedures 
and more than 90 treatments with no local progression, no 
metastatic disease, and no cancer mortality.
Petros et al. [32] reviewed the oncological outcome of ret-
rograde endoscopic management of UTUC in 15 published 
reports. The inclusion criterion was a minimum of 2 years of 
follow-up. The studies differed with regard to the number of 
patients included (10–82, mean 40, median 35), and the total 
number of patients was 597. Recurrences were observed in 
the upper tract in 65% of the patients and in the bladder in 
44%. OS was 35–100%, whereas CSS was 70–100%, pos-
sibly due to disparities in the spectrum of tumour grades 
treated in the various studies. In six of the investigations, 
CSS was 100%. Four of those six studies included only low-
grade tumours in 35, 25, 10, and 10 patients, respectively 
[33–36]. The study with the lowest CSS (70%) had a large 
number of high-grade tumours (two G1, 13 G2, and seven 
G3), whereas the other studies mainly included low-grade 
tumours. Few complications were reported, primarily stric-
tures. Petros et al. concluded that all data supporting endo-
scopic management were based on level 3 evidence, with no 
prospective studies available. The endoscopic ablative tech-
nique was clearly presented in only 8 of the 15 studies, was 
briefly mentioned (with references) in three of the studies, 
and was not mentioned at all in four. However, in the investi-
gations that did consider this technique, holmium (Ho):YAG 
and Ho:YAG in combination with Neodymium:YAG was 
applied most often.
Painter et al. [37] have reported how they changed their 
selection criteria for KSS in patients with UTUC over the 
years. These investigators compared inclusion criteria and 
the outcome of 35 ureteroscopic treatments performed 
during 1998–2006 with 30 procedures carried out during 
2006–2016. In the earlier group, indications were broader, 
and there were six deaths from cancer progression. During 
the period 2006–2016, only endoscopic treatment of low-
risk UTUC was performed, and no patients developed meta-
static disease. The recurrence rate was high in both groups.
In a prospective consecutive study conducted by Villa 
et al. [9], 92 UTUC patients ureteroscopically treated with 
Ho:YAG laser were enrolled over a period of 13 years. The 
median follow-up time was 52 months. In this analysis, 
grade was an independent predictive factor of disease pro-
gression, whereas tumour size ≤ 1 or > 1 cm and multifocal-
ity were not. At 2-year follow-up, progression-free survival 
was 79% for low-grade and 52% for high-grade disease, and 
this difference was statistically significant.
Intravesical recurrence (IVR) has been reported in 
27–40% of UTUC patients after RNU [38]. However, 
Obrien et al. [39] found that the incidence decreased sig-
nificantly when a single dose of intravesical mitomycin was 
given postoperatively. IVR after diagnostic URS has also 
been suggested by several investigators, although these find-
ings have not been found to have an impact on OS, CSS, 
recurrence-free survival, or metastasis-free survival [40–42]. 
Another study showed no correlation between previous uret-
eroscopic tumour ablation and IVR or cancer-specific mor-
tality in patients treated with an upper urinary tract ablation 
prior to RNU [43].
Follow‑up
According to the EAU guidelines, follow-up after RNU 
for low-risk UTUC should include cystoscopy at 3 and 
9 months and thereafter annually, as well as CTU annually. 
For patients with high-risk UTUC, cystoscopy with cytology 
should be performed every 3 months for 2 years, then every 
6 months for 2 years, and thereafter annually for 5 years 
together with CTU annually. After KSS for low-risk UTUC, 
cystoscopy and CTU should be done at 3 and 6 months and 
then annually for 5 years, including URS at 3 months. The 
same programme should be applied for high-risk tumours, 
but adding ureteroscopy with in  situ cytology at 3 and 
6 months. Evidence supporting use of the mentioned follow-
up regimes is weak. Other authors have suggested using both 
a closer and a longer follow-up. Verges et al. [44] described 
a follow-up protocol with URS at 3-month intervals until the 
patient is disease free, followed by URS at 6-month intervals 
for 5 years and thereafter annually, and also annual CTU. 
Some authors strongly recommend a second look in all cases 
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at 6 to 8 weeks after laser ablation [45] (as illustrated in 
Fig. 2).
Discussion
Radical RNU was the gold standard for treatment of all 
patients with UTUC until the EAU guidelines were updated 
during 2011–2013. Before that time, KSS was to be con-
sidered only in imperative cases. However, a better under-
standing of the disease and improved technology have led 
to increased use of kidney-sparing management of UTUC, 
and, along with that, there is a growing need for guidance 
of treatment decisions.
The EAU guidelines have divided UTUC into low- and 
high-risk diseases since 2015 [46]. The update presented 
that year stated that KSS could be considered in low-risk 
patients, whereas the 2018 update recommended that KSS 
be performed in all low-risk cases [5]. Moreover, the defini-
tion of low- and high-risk UTUC has been changed to some 
degree in the 2018 update. Also, the cut-off for tumour size, 
one of the listed prognostic factors, was initially set at < 1 cm 
for low-grade tumours but has now been changed to < 2 cm.
UTUC is a relatively rare disease, and most studies in 
the literature have been retrospective and included limited 
numbers of patients. Consequently, the available evidence 
in this context is relatively weak. Grade and stage have 
been shown to be the strongest prognostic factors [3, 5, 8], 
whereas the significance of tumour size and multifocality 
has been questioned [9, 47]. Direct staging is not possible, 
because endoscopic samples are very small, and deep biop-
sies are associated with the risk of perforation and tumour 
seeding [48]. Still, there is a strong correlation between stage 
and grade, which to some extent does enable indirect staging 
[3, 49, 50]. Clearly, it is essential to achieve correct grad-
ing. However, that task has proven to be challenging for 
endoscopic samples [51, 52], possibly due to the fragility 
of the specimens and the need for careful handling, but also 
because tumour heterogeneity can result in a biopsy that 
does not represent the whole tumour [4, 53, 54].
A critical issue that remains to be solved is distinguish-
ing between aggressive and low-risk UTUC preopera-
tively to serve as indications for KSS or radical surgery. 
Other prognostic factors such as MSI and tissue-based 
molecular markers have been studied [55], and MSI typ-
ing has been shown to aid detection of germline mutations 
and hereditary cancers [20]. The validation of molecu-
lar prognostic biomarkers in biopsy specimens would be 
invaluable in treatment decision-making. Thus far, most 
studies of tissue-based molecular markers have primar-
ily used RNU specimens, although Bagroida et al. [56] 
found high concordance in genomic alterations between 
tumour biopsies and subsequent RNU specimens. None 
Fig. 2  A urothelial carcinoma in the renal pelvis of an 83-y.-o man. 
The tumour has a surface diameter of 17 mm and there are no con-
traindications for RNU. The patient requested KSS, and, after being 
informed of the advantages and disadvantages of such treatment, that 
it might have to be performed in two sessions, and that it will require 
repeated URS, the patient accepted and underwent ureterorenoscopic 
Ho:YAG laser ablation. Second look at 6 weeks after the procedure 
showed a small residual tumour, which was laser treated. Histopathol-
ogy on biopsy showed low-grade (G1–2) UTUC, and cytology also 
showed low-grade disease. The patient had no recurrence at follow-
up 15 months after the last ablation. a Before ablation. b After first 
ablation. c At 6-week second look: one < 1 mm residual tumour was 
found and ablated
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of the investigated markers, neither MSI nor tissue-based 
molecular markers, have yet fulfilled the criteria neces-
sary to support their introduction in daily clinical deci-
sion-making. However, it is plausible that incorporating 
tissue-based markers in prognostic tools in the future can 
help identify patients who would benefit from KSS or 
intensified therapy and monitoring.
The literature concerning long-term results of differ-
ent treatment modalities for UTUC is vast and confusing, 
and most studies have been retrospective. Today, RNU is 
the treatment of choice in all cases of high-risk organ-
confined disease, but RNU entails a significant risk of 
CKD and haemodialysis, the latter of which is associated 
with increased morbidity and mortality [10]. In low-grade 
non-invasive UTUC, endoscopic treatment seems to be 
not only equivalent to RNU with regard to oncological 
outcome, but also saves renal function. Hurel et al. [57] 
found that CSS was similar in patients after KSS or RNU, 
but that OS was better after KSS, possibly due to reduced 
renal function in the RNU group. Lee and co-workers [58] 
compared renal function in 319 patients treated with radi-
cal nephrectomy and 297 patients who underwent RNU, 
and found a greater than threefold higher risk of doubling 
of Cr or dialysis in the RNU patients.
Endoscopic treatment has high local recurrence rates, 
and, in some cases, progression of the disease leads to a 
later RNU. Nevertheless, it may take years for progres-
sion to occur, and endoscopic treatment can save patients 
from long-term suffering with CKD [6, 30]. Increased 
rates of bladder recurrence after diagnostic URS have also 
been reported, and a single dose of intravesical mitomycin 
postoperatively has been discussed. Notably, a systematic 
review and meta-analysis conducted by the EAU guide-
lines panel [59] showed that there are a number of predic-
tors of intravesical recurrence, which are patient specific, 
tumour specific, and treatment specific, but not necessar-
ily linked to preoperative diagnostic URS. Hence, post-
URS mitomycin instillation is still a matter of debate.
The overall goal of risk stratification is to select the 
best option for long-term health. That process entails two 
tasks: the first is to make an accurate diagnosis, and the 
second is to determine the best personalized treatment 
that will lead to a tumour-free status. If KSS is chosen, 
close follow-up with repeated URS and CTU is necessary, 
possibly for the rest of the patients’ lives. Endoscopic 
management requires ‘buy-in’, in other words commit-
ment to long-term surveillance to detect and treat any 
recurrence. On the other hand, radical treatment can lead 
to CKD. Clearly, the patients must be well informed about 
the advantages and adverse effects of both radical treat-
ment and KSS.
Conclusion
Risk stratification in UTUC is feasible and should be done 
in all cases of diagnosed UTUC. The prognostic markers 
used in clinical practice are based primarily on the results 
of retrospective and small studies. To date, the strongest pre-
operative prognostic markers are tumour grade and indirect 
signs of invasiveness and the best way to ascertain these 
preoperatively is URS with in situ samples for cytology and 
histopathology. Investigations of new prognostic markers are 
ongoing, and, hopefully, in the future, diagnostic genomic 
profiling will aid treatment decisions and personalized thera-
peutic approach. KSS seems to have advantages over RNU 
for the treatment of low-grade non-invasive tumours but 
there is a need for prospective long-term follow-up studies 
to confirm this. Moreover, KSS requires multiple follow-up 
procedures, which many patients prefer to avoid and, there-
fore, we need to develop refined models for risk stratification 
and for follow-up.
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